A GLP-1 drug cuts hard cardiovascular events in obesity without diabetes (SELECT)
In SELECT (17,604 adults with cardiovascular disease, BMI >=27, no diabetes), weekly semaglutide 2.4 mg cut major adverse cardiovascular events to 6.5% vs 8.0% on placebo — hazard ratio 0.80 (95% CI 0.72-0.90; P<0.001) over ~40 months (Lincoff et al., NEJM, 11 Nov 2023; NCT03574597). First proof a GLP-1 lowers hard cardiovascular outcomes independent of diabetes — reframing obesity drugs as cardiometabolic medicine with population-scale stakes.
The SELECT trial enrolled 17,604 people with established cardiovascular disease and overweight/obesity but no diabetes. Weekly semaglutide 2.4 mg reduced the composite of CV death, non-fatal MI, or non-fatal stroke — HR 0.80 (95% CI 0.72-0.90; P<0.001) — the first demonstration that a GLP-1 receptor agonist lowers hard cardiovascular outcomes via weight/cardiometabolic pathways, not glycemic control.
Why it matters (spine): human health is half the MTP. A drug class that moves hard endpoints across a huge population reshapes prevention economics and HKG's opportunity surface.
Falsifier: a well-powered contrary RCT/meta-analysis. · Confidence: 0.95.
Provenance: A. Michael Lincoff et al. (Cleveland Clinic; lead investigator, credited), New England Journal of Medicine 2023;389:2221-2232, PMID 37952131, DOI 10.1056/NEJMoa2307563; registered trial NCT03574597.
So we should plan for cardiometabolic, population-scale GLP-1 demand and the adjacent biomarker / monitoring opportunities in HKG.
Treat GLP-1s as cardiometabolic, not cosmetic; budget for population-scale cardiovascular-prevention demand and downstream label expansion.
domains: GLP-1 · cardiometabolic · obesity · clinical-outcomes · longevity